Publication
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Felicia Zhang Perkins, Xiuli Zhang, Yik Yeung Lawrence Yu, Yilin Yang, Darren Cullinan, Kartik Singhal, Carlos A Parra-Lopez, Christopher A Miller, Binghan Yan, Julia W Angkeow, Jinglun Li, Nancy B Myers, Tammi Vickery, John Herndon, Rashmi Mishra, Stephanie Myles, Dominic Sanford, Elizabeth M Jaffee, Daniel A Laheru, Andrea Wang-Gillam, Marianna B Ruzinova, Ian S Hagemann, Sherri R Davies, Timothy P Fleming, Shelby Namen, Carl J DeSelm, Lijin Li, Roheena Z Panni, Feng Gao, Kian-Huat Lim, Obi L Griffith, Malachi Griffith, Robert D Schreiber, S Peter Goedegebuure, William G Hawkins, William E Gillanders
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP)…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT03122106registry_reference1.00
- trialNCT03956056registry_reference1.00
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Registered trialsNCT03122106NCT03956056
Curated evidence
Evidence citing this paper (0)
Data not yet available